News >

Doxorubicin/Ifosfamide Combo for Sarcoma Most Effective in Select Population

Jason Harris
Published: Monday, May 15, 2017

Dr. Robin Young

Robin Young, MBChB, PhD

Chemotherapy with doxorubicin and ifosfamide improved progression-free survival (PFS) and tumor response compared with doxorubicin alone in soft tissue sarcoma, but the combination may be best suited for young, fit patients, according to results published online in Acta Oncologica.

The UPS subgroup had a higher response rate with combination chemotherapy (42.3%) than with doxorubicin (6.9%; OR, 9.90; 95% CI, 1.93-50.7) according to central pathology assessment. Tumor response did not differ significantly between treatment arms for liposarcoma, leiomyosarcoma, synovial sarcoma or “other” subgroups.

Analysis of OS by local pathology assessment showed no interaction between histological subgroup and treatment arm. As assessed by central pathology review, doxorubicin/ifosfamide was associated with improved OS in patients with UPS compared with single-agent doxorubicin (HR, 0.44; 95% CI, 0.26-0.79).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication